A Confluent, Crusty Rash

The global prevalence of AD in older adults increased by 107% between 1990 and 2021, with a greater burden among women and in high sociodemographic regions.

Dupilumab (Dupixent) is the first new targeted therapy for CSU in over a decade.

New data highlight the potential of dupilumab, remibrutinib, and barzolvolimab to expand treatment options for patients with CSU unresponsive to current therapies.

Your daily dose of the clinical news you may have missed.

The investigational botanical zabalafin hydrogel has shown antipruritic, antibacterial, and anti-inflammatory properties, addressing the multifactorial nature of AD.

Black children were 2.4 to 4.1 times more likely to experience early-onset and persistent disease than White peers and much more likely to require urgent care for their AD.